emilio battisti
 Home
EXPO 2015 "NUTRIRE IL PIANETA, ENERGIA PER LA VITA"

TORNA ALL'ELENCO DEI CONTRIBUTI

PETIZIONE SU EXPO 2015 
Se vuoi lasciare il tuo commento, segnalazione o suggerimento su questa iniziativa...

Pagina: <Precedente   ... 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 ...   Successivo>

DanielGal il giorno 26/09/2021 ha scritto:
The compounding of nivolumab and ipilimumab maintained its survival dominance upwards chemotherapy with at least 3 years of backup to each patients with unresectable malign pleural mesothelioma, according to CheckMate 743 measured over results.

Researchers observed the good of the first-line immunotherapy regimen in defiance of patients having been off one's rocker remedial definition after nearly 1 year. The findings, presented during the productive ESMO Congress, also showed no changed refuge signals with nivolumab (Opdivo, Bristol Myers Squibb) head start ipilimumab (Yervoy, Bristol Myers Squibb).

Matter derived from Peters S, et al. Pr‚cis LBA65. Presented at: European Sodality good of Medical Oncology Congress (main converging); Sept. 17-21, 2021.

“Mesothelioma has historically been an damned difficult?to?treat cancer, as it forms in the lining of the lungs less than as a fix aside tumor. It is also an disdainful cancer with defective forecast and 5?year survival rates of there 10%,” Solange Peters, MD, PhD, of the medical oncology services and directorship of thoracic oncology at Lausanne University Salubrity nave in Switzerland, told Healio. “At the the approval of nivolumab annexe ipilimumab, no single systemic treatment options that could specifics survival inasmuch as patients with this acid cancer had been in influence inasmuch as more than 15 years.”

The randomized younger 3 CheckMate 743 experience included 605 patients with untreated pernicious pleural mesothelioma, stratified according to making love and histology (epithelioid vs. non-epithelioid).

Researchers randomly assigned 303 patients to 3 mg/kg nivolumab, a PD-1 inhibitor, every 2 weeks and 1 mg/kg ipilimumab, which targets CTLA-4, every 6 weeks in the mechanic of up to 2 years. The other 302 patients received platinum-based doublet chemotherapy with 75 mg/m2 cisplatin or carboplatin area underneath the curve 5 asset 500 mg/m2 pemetrexed on

Joness#g11ennick[Yjnylobhowvokiho,2,5] il giorno 24/09/2021 ha scritto:
Great

Keith2psync il giorno 21/09/2021 ha scritto:
Thank you

INSERISCI IL TUO COMMENTO:
Nome: (Obbligatorio)
E-mail: (Facoltativo)
N.B. L'indirizzo email viene richiesto solo ad uso interno e
NON sarà in alcun modo reso pubblico.
Commento:



COMMENTA GLI ALTRI CONTRIBUTI

Cos'è

Eventi